Literature DB >> 16307209

The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach.

Lena E Friberg1, Geoffrey K Isbister, L Peter Hackett, Stephen B Duffull.   

Abstract

Defining the pharmacokinetics of drugs in overdose is complicated. Deliberate self-poisoning is generally impulsive and associated with poor accuracy in dose history. In addition, early blood samples are rarely collected to characterize the whole plasma-concentration time profile and the effect of decontamination on the pharmacokinetics is uncertain. The aim of this study was to explore a fully Bayesian methodology for population pharmacokinetic analysis of data that arose from deliberate self-poisoning with citalopram. Prior information on the pharmacokinetic parameters was elicited from 14 published studies on citalopram when taken in therapeutic doses. The data set included concentration-time data from 53 patients studied after 63 citalopram overdose events (dose range: 20-1700 mg). Activated charcoal was administered between 0.5 and 4 h after 17 overdose events. The clinical investigator graded the veracity of the patients' dosing history on a 5-point ordinal scale. Inclusion of informative priors stabilised the pharmacokinetic model and the population mean values could be estimated well. There were no indications of non-linear clearance after excessive doses. The final model included an estimated uncertainty of the dose amount which in a simulation study was shown to not affect the model's ability to characterise the effects of activated charcoal. The effect of activated charcoal on clearance and bioavailability was pronounced and resulted in a 72% increase and 22% decrease, respectively. These findings suggest charcoal administration is potentially beneficial after citalopram overdose. The methodology explored seems promising for exploring the dose-exposure relationship in the toxicological settings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16307209     DOI: 10.1007/s10928-005-0022-6

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  46 in total

1.  Population one-compartment pharmacokinetic analysis with missing dosage data.

Authors:  Dolors Soy; Stuart L Beal; Lewis B Sheiner
Journal:  Clin Pharmacol Ther       Date:  2004-11       Impact factor: 6.875

2.  Analysis of population pharmacokinetic data using NONMEM and WinBUGS.

Authors:  Stephen B Duffull; Carl M J Kirkpatrick; Bruce Green; Nicholas H G Holford
Journal:  J Biopharm Stat       Date:  2005       Impact factor: 1.051

3.  Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects.

Authors:  M Priskorn; F Larsen; A Segonzac; M Moulin
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

4.  Steady-state pharmacokinetics of citalopram in young and elderly subjects.

Authors:  M Gutierrez; W Abramowitz
Journal:  Pharmacotherapy       Date:  2000-12       Impact factor: 4.705

5.  A meta-analysis of prognostic indicators to predict seizures, arrhythmias or death after tricyclic antidepressant overdose.

Authors:  Benoit Bailey; Nicholas A Buckley; Devendra K Amre
Journal:  J Toxicol Clin Toxicol       Date:  2004

6.  Effect of activated charcoal alone or given after gastric lavage in reducing the absorption of diazepam, ibuprofen and citalopram.

Authors:  O Lapatto-Reiniluoto; K T Kivistö; P J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  1999-08       Impact factor: 4.335

7.  Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.

Authors:  J Lu; J M Gries; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

8.  Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans.

Authors:  J Sidhu; M Priskorn; M Poulsen; A Segonzac; G Grollier; F Larsen
Journal:  Chirality       Date:  1997       Impact factor: 2.437

Review 9.  Oral activated charcoal in the treatment of intoxications. Role of single and repeated doses.

Authors:  P J Neuvonen; K T Olkkola
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Jan-Dec

Review 10.  Multiple-dose activated charcoal and enhancement of systemic drug clearance: summary of studies in animals and human volunteers.

Authors:  P A Chyka
Journal:  J Toxicol Clin Toxicol       Date:  1995
View more
  25 in total

1.  Patterns of toxicity and factors influencing severity in acute adult trimipramine poisoning.

Authors:  Karen Gutscher; Christine Rauber-Lüthy; Marina Haller; Michèle Braun; Hugo Kupferschmidt; Gerd A Kullak-Ublick; Alessandro Ceschi
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

2.  The pharmacokinetics of sertraline in overdose and the effect of activated charcoal.

Authors:  Joyce M Cooper; Stephen B Duffull; Ana S Saiao; Geoffrey K Isbister
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

3.  Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose.

Authors:  Geoffrey K Isbister; Lena E Friberg; Stephen B Duffull
Journal:  Intensive Care Med       Date:  2006-05-10       Impact factor: 17.440

4.  Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses.

Authors:  Lena E Friberg; Geoffrey K Isbister; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

5.  Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal.

Authors:  Freek van Gorp; Stephen Duffull; L Peter Hackett; Geoffrey K Isbister
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

6.  Fatal intoxication with antidepressants: a case with many culprits.

Authors:  Antonis Goulas; Nikolaos Raikos; Diamantis Krokos; Orthodoxia Mastrogianni; Amvrosios Orphanidis; Konstantinos Zisopoulos; Androniki Tsepa
Journal:  Forensic Sci Med Pathol       Date:  2018-02-27       Impact factor: 2.007

7.  A Bayesian approach for population pharmacokinetic modelling of sirolimus.

Authors:  Chantaratsamon Dansirikul; Raymond G Morris; Susan E Tett; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2006-10       Impact factor: 4.335

Review 8.  Pharmacokinetic considerations in clinical toxicology: clinical applications.

Authors:  Darren M Roberts; Nick A Buckley
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Mechanism-based pharmacodynamic modeling.

Authors:  Melanie A Felmlee; Marilyn E Morris; Donald E Mager
Journal:  Methods Mol Biol       Date:  2012

Review 10.  Activated charcoal for acute poisoning: one toxicologist's journey.

Authors:  Kent R Olson
Journal:  J Med Toxicol       Date:  2010-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.